Los Angeles Capital Management LLC Has $947,000 Holdings in ANI Pharmaceuticals, Inc. $ANIP

Los Angeles Capital Management LLC trimmed its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 23.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,513 shares of the specialty pharmaceutical company’s stock after selling 4,410 shares during the period. Los Angeles Capital Management LLC owned approximately 0.07% of ANI Pharmaceuticals worth $947,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of the stock. Bryce Point Capital LLC bought a new position in ANI Pharmaceuticals in the 2nd quarter worth approximately $292,000. Emerald Advisers LLC increased its stake in shares of ANI Pharmaceuticals by 414.8% in the 2nd quarter. Emerald Advisers LLC now owns 1,256 shares of the specialty pharmaceutical company’s stock valued at $82,000 after buying an additional 1,012 shares during the period. Mizuho Markets Americas LLC raised its position in shares of ANI Pharmaceuticals by 7.8% during the second quarter. Mizuho Markets Americas LLC now owns 212,830 shares of the specialty pharmaceutical company’s stock worth $13,887,000 after acquiring an additional 15,357 shares during the last quarter. Teacher Retirement System of Texas raised its position in shares of ANI Pharmaceuticals by 3,156.3% during the second quarter. Teacher Retirement System of Texas now owns 147,380 shares of the specialty pharmaceutical company’s stock worth $9,617,000 after acquiring an additional 142,854 shares during the last quarter. Finally, Envestnet Asset Management Inc. lifted its stake in shares of ANI Pharmaceuticals by 59.9% during the second quarter. Envestnet Asset Management Inc. now owns 10,326 shares of the specialty pharmaceutical company’s stock valued at $674,000 after acquiring an additional 3,869 shares during the period. 76.05% of the stock is owned by institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ:ANIP opened at $84.55 on Friday. The firm’s 50 day simple moving average is $92.99 and its 200 day simple moving average is $78.04. ANI Pharmaceuticals, Inc. has a fifty-two week low of $52.50 and a fifty-two week high of $99.50. The company has a market capitalization of $1.83 billion, a price-to-earnings ratio of -109.80 and a beta of 0.54. The company has a debt-to-equity ratio of 1.39, a current ratio of 2.54 and a quick ratio of 1.96.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a negative net margin of 1.37% and a positive return on equity of 25.03%. The business’s quarterly revenue was up 53.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, sell-side analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ANIP has been the subject of a number of research reports. HC Wainwright lifted their price objective on ANI Pharmaceuticals from $93.00 to $121.00 and gave the stock a “buy” rating in a research report on Wednesday, September 17th. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 21st. Guggenheim boosted their price target on shares of ANI Pharmaceuticals from $114.00 to $115.00 and gave the stock a “buy” rating in a research note on Monday. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $77.00 to $90.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Finally, Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $99.29.

Insiders Place Their Bets

In other ANI Pharmaceuticals news, SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, September 19th. The stock was sold at an average price of $98.04, for a total value of $98,040.00. Following the completion of the sale, the senior vice president directly owned 60,186 shares in the company, valued at $5,900,635.44. This represents a 1.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Muthusamy Shanmugam sold 52,988 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, August 21st. The shares were sold at an average price of $90.44, for a total value of $4,792,234.72. Following the transaction, the chief operating officer owned 431,920 shares in the company, valued at $39,062,844.80. This trade represents a 10.93% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 147,281 shares of company stock worth $13,309,804 over the last 90 days. 11.10% of the stock is currently owned by corporate insiders.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.